Evaxion Biotech A/S — Form 6-K Summary
Business context and reporting period
This Form 6-K covers May 2022 and reports resolutions adopted at Evaxion Biotech A/S’s annual general meeting held on May 3, 2022. The company is a Danish foreign private issuer reporting under Form 20-F. The filing was signed on May 19, 2022.
Financial and operating information
- Shareholders approved the audited annual report for the financial year ended 2021.
- The 2021 loss was approved for transfer to the next financial year. The filing text does not provide a clear amount for the loss or other financial metrics such as revenue, cash flow, margins, debt, or liquidity.
- 8,632,126 ordinary shares, representing 37.11% of shares outstanding at the meeting date, were voted.
Material changes and corporate actions
- The board was authorized through May 1, 2027 to increase share capital by up to nominal DKK 47.0 million at market price without pre-emptive subscription rights, including through cash contributions, contributions in kind, or debt conversion. American Depositary Shares may also be issued in connection with such increases.
- The board was authorized through January 3, 2026 to obtain convertible loans of up to nominal DKK 14.7 million and increase share capital by the same amount upon conversion, without pre-emptive subscription rights.
- The board was authorized through May 1, 2027 to issue warrants to investors and/or lenders covering up to nominal DKK 2.0 million of shares and to increase share capital by up to the same amount upon exercise, without pre-emptive subscription rights.
- The historic Article 3.4 was deleted, and the Articles of Association were amended to implement the new authorizations.
- Marianne Søgaard, Lars Holtug, Roberto Prego, and Steven J. Projan were re-elected to the board. Niels Iversen Møller was elected as a new director.
- EY Godkendt Revisionspartnerselskab was re-elected as auditor.
Outlook, risks, and unusual items
- No financial guidance or operating outlook was provided.
- The approved equity, convertible-loan, and warrant authorizations provide financing flexibility but could result in substantial dilution because existing shareholders have no pre-emptive rights.
- Convertible loans and warrants are to be issued at terms determined by the board, subject to the market-price provisions described in the filing.
- The 2021 loss and its carryforward indicate continued losses, but the filing does not provide sufficient information to assess liquidity or going-concern risk.
Investor verification checklist
- Verify the audited 2021 loss, cash balance, cash burn, debt, and remaining liquidity from the annual report.
- Verify the company’s current share count and the potential dilution from the DKK 47.0 million share-capital authorization, DKK 14.7 million convertible-loan authorization, and DKK 2.0 million warrant authorization.
- Review the amended Articles of Association and the terms of any securities issued under these authorizations.
- Confirm the final board composition and auditor appointment in the company’s corporate records.